The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Neostem Inc.  (NBS) Trade Now »     Rate NBS  -  Discuss NBS  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Healthcare Facilities
SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate NBS:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

NBS: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving? Graphic_rating_buy NBS
Mikerun
73%
<> <> On 7/15/09, Cadence Pharma (NASDAQ: CADX) announced that its New Drug Application (NDA) for Acetavance (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the FDA and designated for a priority (six-month) review. The FDA has issued a PDUFA action date for the NDA of 11/13/09 for a possible decision by the Agency. The Company's 505(b)(2) NDA for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and ...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/25/09 1 comment


A Three-Part China Merger Strategy for NeoStem (AMEX: NBS) Graphic_rating_buy NBS
Mikerun
73%
NeoStem (AMEX: NBS) is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of anti-aging / cosmetic medicine and other stem cell technologies. Click here for my mid-September article , which provides an overview and details on the pending China expansion plans as part of a merger that is expected to close by the end of October. <o:p> </o:p> <> <> <o:p>   </o:p> <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/08/09 1 comment


NeoStem (AMEX: NBS): Pending Merger Key to China Growth Strategy Graphic_rating_buy NBS
Mikerun
73%
<> NeoStem (AMEX: NBS) is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cells as a form of bio-insurance for...
By  Mike Havrilla   (+1.04%  risk: conservative)  09/16/09 Comment


Neostem, Inc. Graphic_rating_buy NBS
450vampyr_avatar-med
N/A

<> NeoStem, Inc. (NeoStem), incorporated in September 1980, is engaged in a platform business of operating a commercial autologous (donor and recipient are the same) adult stem cell bank and in pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the United States. It also entered the research and development arenas, through the acquisition of a worldwide license to an early-stage technology to ident...
By  supratrader   (+16.29%  risk: conservative)  06/29/09 Comment


Bullish on NBS ... Graphic_rating_buy NBS
Foto
62%
AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. The Company was recently profiled at BusinessWeek online and will appear in the June 29 print magazine edition.
By  Marian Filo   (-24.55%  risk: aggressive)  06/23/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
FNM Fannie Mae
AAPL Apple Computer Inc
AMD Advanced Micro Devices Inc
MO Altria Group Inc
GS Goldman Sachs Group Inc The
FRE Freddie Mac

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on NBS

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Neostem Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch